Today, Alliance Foundation Trials, LLC (AFT) was informed that the U.S. Food and Drug Administration has approved palbociclib ...
A new collaborative study reports the discovery and application of a novel therapeutic strategy to selectively target EGFR ...
The epidermal growth factor receptor (EGFR) is one of the most extensively studied targets in cancer therapy, yet its complex regulatory mechanisms remain partially understood. While traditional ...
A new collaborative study reports the discovery and application of a novel therapeutic strategy to selectively target EGFR and other kinases with controlled release in tumor microenvironments to ...
Metastatic breast cancer (mBC) remains an incurable disease, and most patients will experience disease progression during their treatment course. Although endocrine therapy remains the mainstay of ...
The epidermal growth factor-like (EGFL) domain is a structural motif found in a family of secreted extracellular matrix proteins, notably EGFL7 and EGFL6, that orchestrate the formation and ...
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial In the article that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results